Sygnature Discovery appoints Susanne Back as Head of In Vivo Pharmacology

pharmafile | May 21, 2026 | Appointment | |  Sygnature Discovery, Vivo Pharmacology 

Sygnature Discovery, an integrated drug discovery contract research organisation (CRO), has announced the appointment of Susanne Back as Head of In Vivo Pharmacology.

Susanne brings 20 years of in vivo pharmacology experience across academia and industry, including senior scientific and leadership roles at Orion Pharma and Charles River. Based in Nottingham. She will lead one of Sygnature’s in vivo pharmacology teams, overseeing approximately 30 scientists and working closely with multidisciplinary project teams and clients to deliver robust in vivo strategies that support informed decision-making across drug discovery programmes.

In her role, Susanne will be responsible for the scientific and operational leadership of the team, including resource planning, workflow optimisation, and the continued development of innovative and competitive in vivo capabilities. She will also provide expert input into study design and act as a key scientific and operational point of contact for clients.

Advertisement

Commenting on her appointment, Susanne Back said: “The co-located, multidisciplinary environment creates a truly collaborative setting where complex discovery challenges can be addressed efficiently.

Fraser McIntosh, VP of in vivo pharmacology at Sygnature Discovery added: “Susanne’s ability to translate project objectives into well-designed in vivo strategies will be instrumental in strengthening our integrated offering.

Looking ahead, Susanne aims to establish a clear scientific and operational strategy for the in vivo pharmacology function.

Related Content

No items found
The Gateway to Local Adoption Series

Latest content